News 2024-03-08
Join Our Founder and CEO @ DCAT Week
Join Our Founder and CEO @ DCAT Week
What:
DCAT Member Company Announcement Forum
When:
10:36-10:43AM, on Monday March 18, 2024
Where:
InterContinental Barclay, Grand Ballroom (2nd Floor)
Porton Pharma Solutions Ltd (hereinafter referred to as Porton or the Company) will participate in the DCAT Week which will be held in New York, from March 18-21, 2024.
As the premiere event in New York City for the Global Bio/Pharmaceutical Manufacturing Value Chain, DCAT Week garners annual industry attention. Porton has consistently participated in this esteemed gathering. At this year’s conference, our Chairman & CEO, Oliver Ju, is scheduled to speak at the DCAT Member Company Announcement Forum on the opening day. He will unveil our latest European and US facilities and capabilities, highlighting how these expansions streamline and enhance our ability to meet your unique development needs with greater ease.
Throughout DCAT Week, the Porton management team, our business development (BD) specialists, and our scientists are eager to connect with you in New York.
Schedule a meeting with us: Arsalan Khan
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
